Please provide your email address to receive an email when new articles are posted on . The Food and Drug Administration (FDA) recently approved an expanded indication for Patanol (olopatadine HCl 0.1 ...

After a 12-day washout, subjects receive 2 days of treatment with Patanol® (commercially available olopatadine eye drops) or placebo eye drops before undergoing another EEC session to assess allergic ...

Review the side-effects of Olopatadine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Please provide your email address to receive an email when new articles are posted on . BASEL, Switzerland — Two affiliates of Novartis International AG have won a ...

Novartis’s Alcon unit won an appeals court ruling that will prevent Apotex Inc. from selling a generic version of the eye drug Patanol until a patent expires in 2015. The U.S. Court of Appeals for the ...

US court decision is an important milestone to defend Alcon's intellectual property rights until the Patanol patent expires in 2015 Basel, May 24, 2011 - Novartis announced today, that two affiliates ...

Wockhardt has received tentative approval from the United States Food & Drug Administration (US FDA) for marketing 0.1 per cent solution of Olopatadine hydrochloride eye drops, used for allergic ...

Co confirms that its subsidiary Barr Laboratories has initiated a challenge of the patents listed by Alcon in connection with Alcon's Patanol 0.1%. Barr filed its Abbreviated New Drug Application ...

New Delhi: Drug firm Wockhardt has received approval from the US health regulator for generic Olopatadine HCl eye drops used for the treatment of opthalmic allergies. The company has received final ...

Novartis International AG / Alcon wins Patanol® US patent infringement lawsuit against Apotex . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of ...